Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of M2SR H3N2 Influenza Vaccines in Healthy Adults
NCT03999554Phase 1Completed
- Sponsor
- FluGen
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza A/Singapore/INFIMH-16-0019/2016(H3N2) in Influenza A (IAV) (5 arms), sponsored by FluGen. Primary endpoint: Number of Participants With Local and Systemic Adverse Events (AEs) at 209 days. Started Sep 2019; status: completed.
02
Drugs
influenza A/Singapore/INFIMH-16-0019/2016(H3N2)
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03999554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999554.